La Jolla, California-based Synthorx Inc, which uses synthetic biology to discover and develop new protein therapeutics, has closed $10 million in Series B financing. RA Capital Management led the round with participation from return backers Avalon Ventures and Correlation Ventures. Also, Dr. Andrew Levin, managing director at RA Capital, has been added to Synthorx’s board of directors.
Source: Press Release
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: